Related Experiment Video

Updated: Jul 14, 2026

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

Antirheumatic drugs and gene signatures

Caroline Ospelt1, Steffen Gay

  • 1University Hospital Zürich, Center of Experimental Rheumatology, Gloriastrasse 23, Zürich, CH-8091, Switzerland. caroline.ospelt@usz.ch

Current Opinion in Investigational Drugs (London, England : 2000)
|May 25, 2007
PubMed

Insights

Microarray technology offers a new approach to rheumatoid arthritis (RA) treatment by analyzing whole-transcriptome gene expression. This method aids in discovering novel therapies and understanding existing drug mechanisms for autoimmune joint destruction.

Area of Science:

  • Immunology
  • Genomics
  • Pharmacology

Background:

  • Rheumatoid arthritis (RA) is a chronic autoimmune disease causing progressive joint destruction.
  • Current antirheumatic drugs often fail to halt disease progression or reverse joint damage.
  • Treatment discontinuation due to toxicity or lack of efficacy is common.

Purpose of the Study:

  • To review the strengths and weaknesses of microarray technology for RA research.
  • To provide an overview of gene expression studies in anti-rheumatic therapies.
  • To highlight the potential of transcriptomics in discovering new RA treatments.

Main Methods:

  • Analysis of whole transcriptome using microarray technology.
  • Gene expression profiling in cells and tissues relevant to RA.
  • Review of current literature on gene expression studies in anti-rheumatic therapies.

Main Results:

  • Microarray technology enables a novel approach to identifying potential RA treatments.
  • This technology aids in understanding the mechanisms of action for existing anti-rheumatic drugs.
  • Gene expression studies offer insights into disease mechanisms and drug responses.

Conclusions:

  • Microarray technology presents a powerful tool for advancing rheumatoid arthritis research.
  • Transcriptomic analysis can accelerate the discovery of more effective RA therapies.
  • Understanding gene expression patterns is crucial for personalized and effective RA treatment strategies.

Related Concept Videos

Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...